Molecular interplay between EIF4 family and circular RNAs in cancer: Mechanisms and therapeutics

Eur J Pharmacol. 2023 Sep 5:954:175867. doi: 10.1016/j.ejphar.2023.175867. Epub 2023 Jun 25.

Abstract

The eukaryotic translation initiation factor 4 (EIF4) family is a major contributor to the recruitment of mRNAs to ribosomes during the initial translation stage in eukaryotes, whose dysregulation either allows for cancer transformation or prevents disordered cancerous cell growth. Circular RNAs (circRNAs), which exhibit distinctive structures and are widely expressed in eukaryotes, are anticipated to be clinical diagnostic biomarkers for cancer therapy. There is considerable evidence that EIF4s can influence the biogenesis, transport, and function of circRNAs and, in turn, circRNAs can control the expressions of EIF4s through certain molecular pathways. Herein, we primarily review the emerging studies of the EIF4 family and pinpoint the roles of dysregulated EIF4s in cancer. We also evaluate the patterns of intricate interactions between circRNAs and EIF4s and discuss the potential utility of circRNA-based therapeutics targeting EIF4s in clinical cancer research.

Keywords: Cancer therapy; Circular RNA; EIF4 family; Interplay.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Peptide Initiation Factors
  • RNA / metabolism
  • RNA, Circular* / genetics
  • RNA, Messenger

Substances

  • RNA, Circular
  • RNA
  • RNA, Messenger
  • Peptide Initiation Factors
  • Biomarkers